RIP3 RIP3 Anticancer supplement composition comprising RIP3 activator Method for screening anticancer supplement agents inducing RIP3 expression for enhancing sensitivity to anticancer agents and method for monitoring sensitivity to anticancer agents

摘要

The present invention relates to a pharmaceutical composition for adjuvant therapy comprising a receptor-interacting protein kinase-3 (RIP3) protein expression promoter or an activator as an active ingredient. The present invention also relates to a pharmaceutical composition comprising an RIP3 protein expression promoter or activator; And an anticancer agent is administered to a cancer cell in combination with the cancer cell. The present invention also relates to a method for screening anti-cancer adjuvants for promoting RIP3 (Receptor-interacting protein kinase-3) expression and thereby enhancing the sensitivity of anticancer drugs, and a method for monitoring the sensitivity of anticancer drugs by expressing RIP3. Therefore, in patients lacking RIP3 expression, induction of RIP3 expression by pretreatment with demethylating agent and concomitant chemotherapy may be an effective therapeutic strategy. In addition, it is expected that it will be an effective strategy to monitor the sensitivity of anticancer drugs in anticancer therapy and to screen anticancer drugs that enhance anticancer drug susceptibility.